US Bancorp DE Boosts Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

US Bancorp DE lifted its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 278.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,356 shares of the company’s stock after acquiring an additional 5,413 shares during the quarter. US Bancorp DE’s holdings in Hims & Hers Health were worth $217,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Allworth Financial LP lifted its stake in Hims & Hers Health by 20.0% in the 1st quarter. Allworth Financial LP now owns 2,006 shares of the company’s stock valued at $56,000 after buying an additional 334 shares in the last quarter. Signaturefd LLC boosted its position in shares of Hims & Hers Health by 17.7% during the 1st quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock worth $76,000 after purchasing an additional 388 shares during the period. Larson Financial Group LLC boosted its position in shares of Hims & Hers Health by 47.7% during the 1st quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock worth $42,000 after purchasing an additional 458 shares during the period. Summit Investment Advisors Inc. boosted its position in shares of Hims & Hers Health by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company’s stock worth $480,000 after purchasing an additional 628 shares during the period. Finally, Cim LLC boosted its position in shares of Hims & Hers Health by 1.0% during the 4th quarter. Cim LLC now owns 71,869 shares of the company’s stock worth $1,738,000 after purchasing an additional 694 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Hims & Hers Health news, insider Michael Chi sold 17,102 shares of the stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total transaction of $1,021,844.50. Following the transaction, the insider owned 278,654 shares of the company’s stock, valued at $16,649,576.50. This trade represents a 5.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Patrick Harrison Carroll sold 60,000 shares of the stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the completion of the sale, the insider directly owned 169,940 shares of the company’s stock, valued at $9,105,385.20. The trade was a 26.09% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,273,034 shares of company stock worth $66,425,573. 13.71% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

HIMS has been the subject of several recent research reports. Citigroup reissued a “sell” rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Needham & Company LLC reiterated a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Morgan Stanley reiterated an “equal weight” rating and set a $40.00 price target on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Truist Financial lifted their price objective on shares of Hims & Hers Health from $45.00 to $48.00 and gave the company a “hold” rating in a research note on Thursday, July 17th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $39.83.

Hims & Hers Health Stock Down 2.2%

HIMS stock opened at $46.09 on Friday. The company has a market cap of $10.32 billion, a P/E ratio of 57.61, a P/E/G ratio of 2.98 and a beta of 2.08. Hims & Hers Health, Inc. has a 52 week low of $13.47 and a 52 week high of $72.98. The company’s 50-day moving average price is $52.96 and its 200 day moving average price is $45.54. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The business had revenue of $544.83 million during the quarter, compared to analysts’ expectations of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm’s revenue for the quarter was up 72.6% on a year-over-year basis. During the same period last year, the company earned $0.06 EPS. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.